Belgium· BE-AMP-SAM663940-00
Kavigale 300 mg
A sipavibart product containing sipavibart, registered in Belgium by AstraZeneca. The same ATC class is registered in 7 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Sipavibart is registered in 7 of 19 countries.
Countries holding a registration under ATC J06BD09 (sipavibart), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 4 of them publish a price we can compare per daily dose
Sipavibart · ATC J06BD09
7 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Sipavibart
- Manufacturer
- AstraZeneca
- Country
- Belgium (BE)
- ATC code
- J06BD09
- ATC class
- Sipavibart
- Defined daily dose
- 0.3 g, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sipavibart in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKAVIGALEAstraZeneca AB, Södertälje
- SpainKAVIGALE 300 MG SOLUCION INYECTABLE Y PARA PERFUSIONAstrazeneca Ab
- FinlandKAVIGALEAstraZeneca AB
- IcelandKavigaleAstraZeneca AB
- PolandKavigaleAstraZeneca AB
- SwedenKAVIGALE 300 mg Injektions-/infusionsvätska, lösningAstraZeneca AB
- IrelandKAVIGALE 300 mg solution for injection/infusionAstraZeneca AB
- NetherlandsKAVIGALE 300 mg oplossing voor injectie/infusieAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kavigale
- Liechtenstein · Kavigale
- Norway · Kavigale
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c0247a1c-584f-4c5f-9650-9bfecfacf284 GET /v1/drugs/c0247a1c-584f-4c5f-9650-9bfecfacf284?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection/infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Kavigale 300 mg",
"name_fr": "Kavigale 300 mg",
"name_nl": "Kavigale 300 mg",
"amp_code": "SAM663940-00",
"strengths": [
"150.0000",
"150.0000",
"0.8000"
],
"pack_count": 1,
"substances": [
"Sipavibart",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Sipavibart",
"authorisation_numbers": [
"EU/1/24/1900/001"
]
}See everything about sipavibart.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.